Society of Laboratory Automation & Screening (SLAS)

Date

Sunday, January 26, 2020 - Thursday, January 30, 2020

Location

San Diego, CA
Charles River has podium presentations, poster presentations and an exhibitor booth at SLAS 2020.

Overview

Charles River is pleased to support the annual meeting of the Society for Laboratory Automation and Screening (SLAS) with a scientific podium session, poster, and educational tutorial session.

Join us at booth 2047 to learn how Charles River combines sophisticated technologies like computer-aided drug design and antibody screening libraries with unmatched expertise in assay development and medicinal chemistry to ensure your HTS campaigns lead to promising developable candidates.

 

Don’t miss our scientists at the following presentations:

Scientific Podium Sessions

Monday, January 27, 2020, 10:30-12:30pm,  Room 6F
Screening & Profiling at higher throughput using physiologically relevant cell models
Roger Clark, BSc, Session Chair

Automating a CRISPR based rescue screen for Alzheimer’s phenotypes in iPSC derived neurons
Shushant Jain, PhD

Alzheimer’s disease (AD) is a complex disorder with increasing prevalence and socio-economic burden. However, majority of strategies aimed at identifying therapies for AD have been focused on targeting Abeta or TAU, which make up the plaques and tangles respectively commonly found in people with AD. Continued failure of the drug discovery process and the accompanying trials against these targets has necessitated more and better options for therapeutic intervention.

Using a multi-parametric high content phenotypic readouts with neurons derived from human differentiated iPSCs with familial AD mutations, we will perform CRISPR based rescue screen for the various phenotypes associated with the mutations, such as endolysosomal transport, synaptic dysfunction, neuronal toxicity. The multiple-phenotypic rescue approach will enable identification novel key pathways and/or targets which could serve has drug candidates for the treatment of AD.

At this session, Charles River will be introducing a recent collaboration with Bit Bio, a company that offers consistent and efficient reprogramming of human cells for use in research, drug discovery, and cell therapies. After the session, stop by booth 2047 from 2:30-6:00pm to discuss this new capability with Charles River and Bit Bio scientific leadership.

 

Tutorial Session

Tuesday, January 28, 2020, 12:30-1:15pm,  Room 10
Protein target class as a determinant of compound purity in screening hits: How to determine appropriate quality control processes and suitable assay conditions for a particular target class and how to guide decisions on library composition | David Cronk, PhD

There has been much focus in the industry for many years on the quality of compounds within screening collections and the impact of storage conditions on overall compound purity and as a result, screening libraries have improved over the years. There has also been some effort placed into understanding the susceptibility of assay formats to particular chemical classes but little has been done to evaluate the impact of the target proteins themselves.

We will share our data where we retrospectively reviewed the purity of hit compounds identified from high throughput screening campaigns to look for trends in the overall compound purity pass rates. This study has revealed that the nature of the target class screened as well as the assay conditions lead to a marked difference in the overall number of compounds that pass set purity thresholds. These data can then be used to determine appropriate quality control processes, suitable assay conditions for a particular target class and guide decisions on library composition and the selection of new compounds to be added to a screening collection.

 

Scientific Posters

Adenovirus-Mediated CRISPR/Cas9 Gene Editing in Patient Primary Fibroblasts to Validate Potential Drug Targets in Lung Fibrosis | Roger Clark

Validation of the interaction between a candidate compound and the intended drug target by a phenotypic rescue approach | Shushant Jain, PhD

Development and validation of NMDA receptor ligand-gated ion channel assays using the Qube 384 automated electrophysiology platform | Roger Clark

High Content Imaging (HCI) of disease-relevant cellular models for target and phenotypic drug discovery | Roger Clark

Molecular and functional characterization of stem cells-derived glutamatergic neurons (ioNEURONS/glut) in support of drug discovery applications | Shushant Jain, PhD

Adaptive voltage protocols increase precision of voltage-gated ion channel measurements on high-throughput automated patch clamp platforms | David Cronk, PhD

First-in-class meets best-in-class: Rapid antibody discovery on hard targets combined with fine-grained engineering and optimization | Blisseth Sy

For additional information on our conference participation or to schedule a meeting with our attending scientists, please email [email protected].